NCT01218230

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

A Clinical Trial to Study the Efficacy and Safety of Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: L.V. Prasad Eye Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Intravitreal pegaptanib for treatment of choroidal neovascularisation secondary to pathologic myopia

Detailed description

This is a Prospective Interventional, non-comparative study in 20 consecutive patients who will be selected from the outpatient services. After taking an informed consent, the patients will be given intravitreal Pegaptanib 0.3 mg every 6 weeks for 3 procedure of injection. Thereafter, patients will continue to be examined every 6 weeks (± 2 weeks) and of may receive additional injections as needed based on the presence of one or more re-treatment criteria (please see below). Final assessment will be done at 54 weeks and all the baseline investigations will be performed.

Conditions

• Myopic Choroidal Neovascular Membrane

Interventions

Type	Name	Description
DRUG	Intravitreal Pegaptanib	Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.

Timeline

• Start date: 2010-12-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2010-10-11
• Last updated: 2015-09-02

Locations

1 site across 1 country: India